Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company
December 16, 2019 11:11 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Dec. 16, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune", “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a...
Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change
October 28, 2019 09:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical...
Immune Therapeutics, Inc. Announces Advisory Board Appointments
October 22, 2019 11:03 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company...
Immune Therapeutics Inc. Management Advises All Shareholders to Vote Their Proxy Card Today
September 26, 2019 09:00 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors
September 23, 2019 09:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation...
Immune Therapeutics Revises and Resends Proxy Statement
September 10, 2019 09:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 10, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics, Inc. Provides Shareholder Update on 14A
May 15, 2019 09:36 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics welcomes Kevin Phelps to Board of Directors
January 09, 2019 13:44 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Jan. 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune Therapeutics”, “IMUN” or the “Company”), a late stage clinical biopharmaceutical...
Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine
December 13, 2018 10:24 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Dec. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors
September 06, 2018 09:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation...